Although currently there are no available agonists for PRDM16, it has been shown that PPARγ agonists could potently increase the half-life of the PRDM16 protein (45) and PPARγ agonists attenuate inflammation in aortic aneurysm patients (46). Here, PRDM16 is linked to aortic aneurysm.